Is telehealth allowed to prescribe Strattera in Illinois?

Introduction: Understanding Telehealth Options for ADHD Non-Stimulants

If you’re seeking treatment for ADHD but prefer non-stimulant options like Strattera (atomoxetine), you may be wondering if telehealth is a viable path. The good news is that across all 50 states, non-stimulant ADHD medications can generally be prescribed through telehealth without the strict requirements that apply to controlled substances. Unlike stimulant medications (Adderall, Ritalin, etc.), non-stimulants don’t carry the same regulatory burden because they aren’t controlled substances with abuse potential.

This comprehensive guide explains the current telehealth landscape for non-stimulant ADHD medications, highlighting the key differences between state laws and what patients should expect from a legitimate telehealth provider. We’ll cover everything from the federal regulatory status to state-specific requirements, helping you understand your options for accessing these medications safely and conveniently.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: Why Non-Stimulants Are Different

The DEA’s Current Position

A critical distinction to understand is that Strattera (atomoxetine) and other non-stimulant ADHD medications are not controlled substances. This means they are not subject to the Drug Enforcement Administration’s (DEA) special requirements for telehealth prescribing.

While the DEA currently has temporary rules in place through December 31, 2025, allowing telehealth prescribing of controlled substances without prior in-person exams, these rules don’t impact non-stimulant prescriptions. Non-stimulants have always been prescribable via telehealth, even before the pandemic, and will remain so regardless of what happens with the DEA’s temporary rules.

The Ryan Haight Act Doesn’t Apply

The Ryan Haight Online Pharmacy Consumer Protection Act typically requires an in-person medical evaluation before prescribing controlled substances. However, this requirement explicitly does not apply to non-controlled medications like Strattera. This means providers can legally evaluate patients and prescribe non-stimulants via telehealth without meeting the in-person examination requirement.

State-by-State Telehealth Rules for Non-Stimulant ADHD Medications

While federal law permits telehealth prescribing of non-stimulants, state laws still govern how healthcare is delivered. Here’s what you need to know about key states:

California

California has embraced telehealth, with no special restrictions for non-stimulant medications. There is no state-mandated in-person exam requirement for medications like Strattera. California allows nurse practitioners (NPs) independent practice authority after meeting experience requirements, meaning they can prescribe non-stimulant ADHD medications without physician oversight.

New York

New York permits telehealth prescribing of non-stimulants without requiring in-person visits. While NY implemented stricter rules for controlled substances in 2025 (requiring in-person evaluation before prescribing any controlled substance), these restrictions don’t affect non-stimulant medications. Nurse practitioners in New York can practice independently after 3,600 hours of experience, allowing them to prescribe medications like Strattera.

Florida

Florida allows telehealth prescribing of non-stimulant ADHD medications without any special requirements. There is no in-person exam mandate for these medications. While Florida does have restrictions on telehealth prescribing of controlled substances, these don’t apply to non-stimulants like Strattera. Florida requires nurse practitioners to work under physician collaboration.

Texas

Texas is telehealth-friendly for mental health treatment, including ADHD. There is no in-person requirement for prescribing non-stimulant medications via telehealth. Texas requires nurse practitioners to practice under physician delegation, but they can prescribe non-controlled medications like Strattera under this arrangement.

Other Notable States:

• Alabama: While Alabama has one of the country’s stricter telehealth laws (requiring an in-person visit within 12 months for ongoing telehealth treatment), mental health services are exempt from this requirement. Non-stimulant ADHD medications can be prescribed via telehealth.

• New Hampshire: Recently updated its telehealth laws to be more permissive. For non-controlled medications like Strattera, there are no special telehealth requirements.

• Georgia: Allows telehealth prescribing of non-stimulant medications without an in-person requirement. However, Georgia restricts nurse practitioners from prescribing Schedule II controlled substances (which wouldn’t affect non-stimulants).

Quick Reference: Strattera (Atomoxetine) Telehealth Prescribing

What to Expect from a Legitimate Telehealth ADHD Evaluation

A proper telehealth evaluation for ADHD should be comprehensive, regardless of whether you’re seeking stimulants or non-stimulants. Here’s what a quality assessment includes:

1. Thorough Initial Evaluation

Expect a video consultation lasting 30-45 minutes where the provider will:

• Review your medical history and any previous ADHD evaluations
• Assess your symptoms using standardized diagnostic criteria
• Ask about your functioning in various settings (work, home, school)
• Screen for other conditions that might cause similar symptoms
• Discuss medication options, including non-stimulants like Strattera

At Klarity Health, our providers follow evidence-based protocols to ensure proper diagnosis and treatment planning, whether you’re seeking stimulant or non-stimulant options.

2. Informed Consent and Education

A legitimate provider will:

• Explain how Strattera works (it increases norepinephrine in the brain)
• Discuss that it typically takes 4-6 weeks to reach full effectiveness (unlike stimulants that work immediately)
• Review potential side effects (which can include nausea, decreased appetite, fatigue, and possible blood pressure changes)
• Set realistic expectations about treatment outcomes

3. Regular Follow-Up Appointments

Even though non-stimulants don’t require the same monitoring as controlled substances, proper care includes:

• An initial follow-up within 2-4 weeks to assess early response and side effects
• Regular check-ins to monitor effectiveness and adjust dosing
• Periodic reassessment of symptoms and treatment goals

Common Misconceptions About Non-Stimulant ADHD Telehealth Treatment

Misconception #1: ‘Non-stimulants aren’t effective for ADHD’

Reality: While stimulants are often first-line treatments, non-stimulants like Strattera can be very effective for many patients. They’re especially helpful for people who can’t tolerate stimulant side effects, have anxiety disorders, substance use concerns, or cardiovascular issues that make stimulants risky.

Misconception #2: ‘The telehealth evaluation for non-stimulants is less thorough’

Reality: Legitimate telehealth providers should conduct equally thorough evaluations regardless of medication type. The assessment process for determining if you have ADHD should be the same whether you end up with a stimulant or non-stimulant prescription.

Misconception #3: ‘I’ll get denied treatment if I ask for a non-stimulant instead of Adderall’

Reality: Reputable providers won’t penalize you for preferring non-stimulants. In fact, many clinicians appreciate patients who are open to these options, as they can indicate a focus on symptom management rather than seeking a specific controlled medication.

Tips for Telehealth ADHD Treatment with Non-Stimulants

1. Choose a reputable telehealth provider with licensed medical professionals who specialize in ADHD.

2. Be prepared to share your full medical history, including any previous ADHD treatments, other medications you’re taking, and any mental health conditions.

3. Set realistic expectations about timing – unlike stimulants which work immediately, Strattera and other non-stimulants may take 4-6 weeks to

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment